Ulonivirine

Phase 1Small molecule

Merck & Co.

Ulonivirine is one of 37 small molecule programs targeting Hepatic Insufficiency. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Hepatic InsufficiencyNot yet recruiting

Clinical TrialActive, not recruiting

Hepatic InsufficiencyPhase 1

Not yet recruiting

Clinical TrialPhase 1

Active, not recruiting

Competition

Competitive Landscape

127 competitors in Clinical Trial

#DrugCompanyPhaseTrials

Gemzar

Johnson & Johnson

Phase 3

3 2

Avelox

Bayer

Phase 3

2 3

Venclexta

AbbVie

Phase 3

2 4

Paraplatin

AAvyxa

Phase 3

2 5

Opzelura

DDizal Pharmaceuticals

Phase 3

1 6

Potassium Iodide

MMeda Pharmaceuticals

Phase 3

1 7

Ablysinol

CSL Behring

Phase 3

1 8

Nascobal

GGrupo Espanol de Tumores Neuroendocrinos

Phase 3

1 9

JOINTSTEM

RR-Bio

Phase 3

2 10

MCV4

CanSino Biologics Inc.

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2027

Phase 1Recruiting

Study completion

NCT07595263

Q2 2027

Phase 1Not yet recruiting

Hepatic Insufficiency

NCT05093972

Clinical

Trials by Indication[1]

Immunodeficiency2 trials

Evaluation of Safety, Tolerability, Pharmacokinetics, and Antiretroviral Activity of Ulonivirine (MK-8507) in Human Immunodeficiency Virus (HIV-1)-Infected Participants (MK-8507-003)

Completed· Merck & Co. logo

Merck & Co.·Phase 1·NCT02174159·18 enrolled

Dose Ranging, Switch Study of Islatravir (MK-8591) and Ulonivirine (MK-8507) Once-Weekly in Virologically-Suppressed Adults With Human Immunodeficiency Virus Type 1 (HIV-1) [MK-8591-013]

Completed· Merck & Co. logo

Merck & Co.·Phase 2·NCT04564547·161 enrolled

Adult1 trial

A Study of [14C]Ulonivirine ([14C]MK-8507) in Healthy Adults (MK-8507-006)

Completed· Merck & Co. logo

Merck & Co.·Phase 1·NCT07334886·8 enrolled

Clinical Trial1 trial

A Clinical Trial to Evaluate the Effect of Ulonivirine (MK-8507) on Heart Rhythm in Healthy Adults (MK-8507-012)

Active, not recruiting· Merck & Co. logo

Merck & Co.·Phase 1·NCT07305831·62 enrolled

Hepatic Insufficiency1 trial

An Open-Label, Single-Dose Clinical Study to Evaluate Pharmacokinetics of MK-8507 in Participants With Mild or Moderate Hepatic Impairment.

Not yet recruiting· Merck & Co. logo

Merck & Co.·Phase 1·NCT05093972·22 enrolled

Unspecified1 trial

A Clinical Trial to Study the Effect of a Single Dose of Ulonivirine on the Pharmacokinetics of Methadone

Recruiting· Merck & Co. logo

Merck & Co.·Phase 1·NCT07595263·14 enrolled

Sources

References

[1]
ClinicalTrials.gov — 6 trial records for Ulonivirine. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Ulonivirine compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Ulonivirine. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Merck & Co. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: Merck & Co.

Ulonivirine

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2027

Q2 2027

Trials by Indication[1]

Immunodeficiency2 trials

Adult1 trial

Clinical Trial1 trial

Hepatic Insufficiency1 trial

Unspecified1 trial

References

Drug Info

Quick Facts

Related News